Kalvista Pharmaceuticals Inc

NASDAQ KALV

Data sourced from

and

Download Data

Kalvista Pharmaceuticals Inc Return on Net Investment (RONI) for the Trailing 12 Months (TTM) ending January 31, 2024

Kalvista Pharmaceuticals Inc Return on Net Investment (RONI) is NA for the Trailing 12 Months (TTM) ending January 31, 2024. Return on net investment measures the profitability of a company relative to its net investment, which includes total investments minus short-term investments and long-term debt. It is calculated by dividing the net income by the net investment. This ratio provides insights into the return generated for each unit of net investment made by the company. A higher return on net investment indicates better profitability and efficient utilization of the company's invested capital.

NASDAQ: KALV

Kalvista Pharmaceuticals Inc

CEO	Mr. Thomas Andrew Crockett M.B.A.
IPO Date	April 9, 2015
Location	United States
Headquarters	55 Cambridge Parkway, Cambridge, MA, United States, 02142
Employees	118
Sector	Healthcare
Industry	Biotechnology

Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Key trends